Nephrotic Syndrome – Definition, Diagnostic Criteria, and Clinical Implications

Definition

• Nephrotic syndrome is characterized by heavy proteinuria (≥3.5 g/day in adults or ≥40 mg/m²/h in children), hypoalbuminemia (<3.0 g/dL in adults or ≤2.5 g/dL in children), and peripheral edema; hypercholesterolemia is frequently present but not required for diagnosis. 1

Core Diagnostic Criteria

Proteinuria Thresholds

• In adults, a 24‑hour urine protein excretion of ≥3.5 g/day or a spot urine protein‑to‑creatinine ratio (UPCR) >3.5 g/g confirms the proteinuria component. 1
• In children, nephrotic‑range proteinuria is defined as ≥40 mg/m²/h (or ≥1.0 g/m²/day); a first‑morning spot UPCR ≥2 g/g is an acceptable surrogate, and it has replaced 24‑hour collections because of ease of use and strong correlation with timed collections. 2

Hypoalbuminemia Cutoffs

• Adults are diagnosed when serum albumin is <3.0 g/dL. 1
• For children, the traditional threshold of ≤2.5 g/dL is retained by the 2023 KDOQI US Commentary, despite a 2021 KDIGO suggestion to raise it to <3.0 g/dL, because of insufficient evidence and the need for consistency with five decades of trial data. 2

Edema Requirement

• The presence of peripheral edema (often periorbital in the morning and dependent pitting later in the day) is mandatory for the diagnosis of nephrotic syndrome. 1

Associated Clinical Features (Not Required for Diagnosis)

• Hypercholesterolemia commonly accompanies nephrotic syndrome but is not part of the formal definition. 1
• The risk of thromboembolism rises markedly when serum albumin falls below 2.9 g/dL; however, this threshold may vary according to the albumin assay method used. 3

Laboratory Considerations

• Serum albumin measured by bromocresol green (BCG) assays tends to overestimate true albumin concentrations in nephrotic patients compared with bromocresol purple (BCP) assays, influencing risk assessment for thromboembolism. 4

Prognostic Significance

• Patients with proteinuria >3.8 g/day have an estimated 35 % risk of progressing to end‑stage renal disease within two years, versus a 4 % risk for those with proteinuria <2.0 g/day. 5
• Each 1.0 g/dL decrement in serum albumin is associated with an 89 % increase in odds of morbidity and a 137 % increase in odds of mortality. 5

Diagnosis and Classification of Primary Nephrotic Syndrome

Epidemiology and Histologic Subtypes

• Minimal change disease is the most common cause of primary nephrotic syndrome in children and requires kidney‑biopsy confirmation in adults, according to Kidney International (2021) 6.

Classification of FSGS

• The 2021 KDIGO guidelines classify focal segmental glomerulosclerosis (FSGS) into four categories—primary (immunologically mediated and responsive to immunosuppression), genetic, secondary (viral, drug‑induced, or adaptive hyperfiltration), and undetermined cause [7][8].

Diagnostic Criteria for Primary FSGS

• Primary FSGS is identified when a patient with an FSGS lesion on biopsy has (a) proteinuria > 3.5 g/day and serum albumin < 3.0 g/dL, (b) diffuse foot‑process effacement on electron microscopy, and (c) often a sudden onset of full nephrotic syndrome [9][10].
• Patients who present with nephrotic‑range proteinuria but serum albumin > 3.0 g/dL, or with proteinuria < 3.5 g/day, should first be evaluated for secondary etiologies and for genetic forms before initiating immunosuppressive therapy [9][10].

Genetic Considerations

• In adults with steroid‑resistant FSGS, genetic testing reveals disease‑causing variants in 11–24 % of cases, most commonly in type IV collagen or podocyte‑specific genes [7][8].
• Individuals whose FSGS is genetically mediated are markedly less likely to respond to immunosuppressive agents and have a lower risk of disease recurrence after kidney transplantation [7][8].

Biopsy Indications

• Kidney biopsy is mandatory for all adults with suspected primary nephrotic syndrome to confirm the underlying histology 6.
• Atypical clinical features that prompt biopsy include persistent hematuria, rapidly declining estimated glomerular filtration rate, low eGFR with minimal proteinuria, or the absence of other diabetic complications in patients with diabetes 11.

KDIGO 2021 Updates on Glomerular Disease Classification and Management

Complement‑Mediated Glomerulopathies

• The modern classification recognizes C3 glomerulopathy as a complement‑driven disorder that includes dense‑deposit disease, reflecting its distinct pathogenesis from immune‑complex diseases. [Kidney International 2021] 12

Redefinition of the Membranoproliferative Pattern

• KDIGO 2021 replaced the historic term “membranoproliferative glomerulonephritis” with “glomerular diseases mediated by immunoglobulins and complement with an MPGN pattern,” emphasizing the underlying immunopathology rather than a purely morphologic label. [Kidney Disease: Improving Global Outcomes 2021] 12, 13

Focal Segmental Glomerulosclerosis (FSGS) Classification and Therapeutic Implications

Four‑Category Classification

• KDIGO 2021 categorizes FSGS into four distinct groups:

Reorganization for Treatment Decision‑Making

• The KDIGO 2021 FSGS chapter was reorganized to help clinicians differentiate primary, immunosuppressible forms from secondary or genetic variants, thereby guiding when immunosuppressive therapy is appropriate and when it should be avoided. [Kidney Disease: Improving Global Outcomes 2021] 13

Biomarkers for Primary Membranous Nephropathy (MN)

• KDIGO 2021 now classifies primary MN unequivocally as an autoimmune disease and recommends routine monitoring of pathogenic auto‑antibodies (e.g., anti‑PLA2R) to assess disease activity and guide therapy, enabling a more precise, biopsy‑sparing management approach. [Kidney Disease: Improving Global Outcomes 2021] 12, 13

Evidence level for these recommendations was not explicitly stated in the cited sources.